Disease Characteristics: OTCD is a rare, X-linked genetic disorder that is characterised by complete or partial lack of the OTC enzyme. OTC enzyme is a key component of the urea cycle and patients with OTCD accumulate nitrogen waste in the form of excess ammonia (hyperammonaemia) in the blood, causing hyperammonaemic decompensations with symptoms including vomiting, impaired voluntary movement and progressive lethargy. If left untreated, these may progress to coma and life-threatening complications. While later onset disease can occur in adults with a milder form of the disorder, symptoms present within a few days of birth of males with severe OTCD. Patients are rapidly diagnosed (urine and blood biochemical analyses, gene sequencing) when they present at hospital/are admitted to intensive care with acute hepatic decompensation and hyperammonaemia.
Unmet Need: Current standard of care involves protein-restricted diets and ammonia-scavenger medications; however, these approaches can have a significant impact on patients’ quality of life and patients still face a lifelong risk of decompensation and neurological damage resulting in intellectual disability, developmental delays, and movement disorder. Liver transplant is the only curative option, but is often unavailable and comes with significant morbidity/mortality risk and lifelong immunosuppression and arginine supplementation.
Epidemiology: Over 10,000 patients suffering from OTCD have been identified worldwide.
BGT-OTCD was initially developed by Prof Ian Alexander and Associate Prof Leszek Lisowski of Children’s Medical Research Institute (CMRI) in Westmead, Australia, in collaboration with Prof Gissen from UCL.
BGT-OTCD has received Orphan Drug Designation from the European Commission (EC) and the U.S. Food and Drug Administration (FDA), as well as Rare Pediatric Disease Designation (RPDD) from the FDA for the treatment of OTCD. BGT-OTCD is currently being evaluated in HORACE (Halting Ornithine transcarbamylase deficiency with Recombinant AAV in ChildrEn, NCT 05092685), a Phase 1/2 clinical trial initiated in November 2023.
Baruteau J, Cunningham SC, Yilmaz BS, et al. Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Mol Ther Methods Clin Dev. 2021;23:135-146. Published 2021 Sep 14. doi:10.1016/j.omtm.2021.09.005
Cunningham SC, van Dijk EB, Zhu E, et al. Recapitulation of skewed X-inactivation in female OTC-deficient primary human hepatocytes in the FRG mouse: a novel system for developing epigenetic therapies [published online ahead of print, 2023 Jun 23]. Hum Gene Ther. 2023;10.1089/hum.2023.011. doi:10.1089/hum.2023.011
Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506(7488):382-386. doi:10.1038/nature12875
Vercauteren K, Hoffman BE, Zolotukhin I, et al. Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol Ther. 2016;24(6):1042-1049. doi:10.1038/mt.2016.61
Cabanes-Creus M, Hallwirth CV, Westhaus A, et al. Restoring the natural tropism of AAV2 vectors for human liver. Sci Transl Med. 2020;12(560):eaba3312. doi:10.1126/scitranslmed.aba3312
Cabanes-Creus M, Westhaus A, Navarro RG, et al. Attenuation of Heparan Sulfate Proteoglycan Binding Enhances In Vivo Transduction of Human Primary Hepatocytes with AAV2. Mol Ther Methods Clin Dev. 2020;17:1139-1154. Published 2020 May 13. doi:10.1016/j.omtm.2020.05.004
Biswas M, Marsic D, Li N, et al. Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity. Mol Ther Methods Clin Dev. 2020;19:347-361. Published 2020 Oct 4. doi:10.1016/j.omtm.2020.09.019
George LA, Monahan PE, Eyster ME, et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021;385(21):1961-1973. doi:10.1056/NEJMoa2104205
Zhang S, Bastille A, Gordo S, et al. Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia. PLoS One. 2022;17(9):e0274774. Published 2022 Sep 20. doi:10.1371/journal.pone.0274774
Cabanes-Creus M, Navarro RG, Liao SHY, et al. Characterization of the humanized FRG mouse model and development of an AAV-LK03 variant with improved liver lobular biodistribution. Mol Ther Methods Clin Dev. 2023;28:220-237. Published 2023 Jan 2. doi:10.1016/j.omtm.2022.12.014
Cabanes-Creus, M., Liao, S.H.Y., Gale Navarro, R. et al. Harnessing whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation. Nat Commun 15, 1876 (2024). https://doi.org/10.1038/s41467-024-46194-y
National Urea Cycle Disorders Foundation (NUCDF) https://nucdf.org/
Metabolic Support UK https://metabolicsupportuk.org/
